歌礼制药-B计划于2026年第三季度向美国FDA提交ASC39口服片剂新药临床试验申请

美股速递
Mar 17

歌礼制药-B近日披露重要研发进展,公司计划在2026年第三季度向美国食品药品监督管理局提交ASC39口服片剂的新药临床试验申请。这一时间节点的明确标志着该创新药物研发进程进入关键阶段,为后续临床开发奠定重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10